The explosion in surgical technological techniques has been accompanied by questions about actual improvements in outcome and cost-effectiveness. At present, the main procedures for which robotic surgery has been approved are limited to procedures requiring deft and accurate manipulations in limited spaces such as the uterus, and the prostate, since governmental and insurance agencies question the real outcome efficiency and cost benefit performance (CBP) of robot-assisted surgery (RAS) in comparison to video-assisted surgery (VAS) in larger organs.
While RAS has been approved for insurance compensation only in prostate surgery in Japan, robot-assisted thoracic surgery (RATS) has not yet been approved for reimbursement by the Japan National Health Insurance System (JNHIS).
The cost of RAS in Japan is of course greatly affected by the cost of the operator-controlled module, the ancillary equipment and maintenance costs, but not by the surgeon's fee, since in university hospitals in Japan, surgeons are paid a salary determined by the Ministry of Health and Welfare, regardless of the number or types of surgical procedures they perform.
Methods
All patients who underwent RATS in our hospital provided written informed consent after full explanation of the investigational nature of the procedures, and the study was approved by the institutional review board. We performed this institution-funded trial in 20 cases of mediastinal tumors, chest wall tumors and lung cancer, in order to establish the technique of RAS procedures and determine its medicoeconomic aspects in thoracic diseases. All procedures were performed between March 2010 and July 2012 and all costs were borne by the hospital in all cases. All data included in the figures and tables are calculated at ¥80 = $1, which was the average exchange rate as between March 2010 and July 2012.
Instruments
We employed the da Vinci ® Surgical System (dVS) (Intuitive Surgical, Inc., Sunnyvale, California, USA), as described in our previous reports. [1] [2] [3] The techniques and costs of preoperative workup, anesthesia and postoperative management are essentially the same for RATS and video-assisted thoracic surgery (VATS). The establishment of the four access ports was similar in RATS and VATS. The uniquely different features of RATS are the use of the EndoWrist (the monopolar curved scissors for Arm #1, and Maryland bipolar forceps or Cadiere forceps for Arm #2) and inflation of the typically narrow working thoracic space with high-pressure CO 2 (8-10 mmHg).
Role of the funding source
All medical expenses for actual medical examinations and treatment for patients were paid for by Tokyo Medical University Hospital. For research support for studies on robotic surgery, we used a grant from the Cancer Research Institute of Tokyo Medical University.
Results
We compared the costs for RATS and VATS, as decreed by the JNHIS, with RATS for each of the above-mentioned thoracic procedures in the US and Japan (Tables 1 and 2 ). Although the additional costs varied according to the type of procedure, in general the use of RATS increased costs by over $10000 per procedure in Japan (Table 1A) . However, when we examine the costs according to procedure and according to whether the disease is benign or malignant, we can see that, while, in general, uniform non-RATS procedures cost less in Japan than in the US, perhaps because of the nationally implemented policy of the JNHIS, the use of RATS in Japan almost doubles the cost of open procedure due to the high cost of robotic equipment. Robot-assisted prostatectomy for prostate cancer now receives insurance reimbursement for use of support devices for endoscopic surgery, $6775 under the JNHIS, since April 2012. If the same standard amount were applied to various diseases in the field of general thoracic surgery, the additional cost for RATS, which would also require set-up of the support devices for endoscopic surgery, $6775 which is the same as robotic prostatectomy under the JNHIS, on the basic cost of open thoracotomy approach.
Calculations of costs associated with robotic medical care for institutions which perform dVS-operations 100 times (A), 200 times (B) or 300 times (C) annually, are shown in Table 1B . In the JNHIS, reimbursement is based on the insurance point number awarded for a given procedure or the equipment used. The difference of cost for dVS surgery in Table 3 varies on the assumption of between 100, 200 or 300 robotic cases in a year at one institution with the JNHIS (Table 3) . Figure 1 shows the difference between open thoracotomy procedures and RATS procedures, when institutions $11684*** Table 1A shows the cost for the da Vinci ® Surgical System (dVS) operation on the assumption of 100 cases in 1 institution per year with the projected Japanese National Health Insurance System (JNHIS) reimbursement system. *repayment cost/operation, **running cost/operation, ***cost/ one-robotic case operation, # medical materials cost for the dVS/operation • $3255000 (purchase price of the dVS) × 0. = $6278***/one-robotic case operation Table 1B shows a tentative calculation for the basis of costs associated with robotic medical care for institutions which perform the da Vinci ® Surgical System (dVS) procedures 100 times (pattern A), 200 times (pattern B) and 300 times (pattern C) in a year, respectively. *repayment cost/operation, **running cost/operation, ***cost/one-robotic case operation, # medical materials cost for the dVS/operation; † Reduced by Intuitive Surgical to US$90000 (maintenance cost/year) from July 2012.
Discussion
In Japan, prostectomy for prostate cancer using the dVS is the only application recognized for reimbursement by the JNHIS of the Ministry of Health, Labour and Welfare, and this has been only since April 2012. We are still waiting for recognition by the Ministry of Health, Labour and Welfare for reimbursement of dVS operations in other clinical fields, such as gastrectomy, uterectomy, pulmonary lobectomy and thymectomy. Nevertheless, dVS Table 2 shows the cost for dVS-surgery for 100 robotic cases per year at 1 institution with the projected JNHIS reimbursement system. RATS: robot-assisted thoracic surgery; VATS: video-assisted thoracic surgery; JNHIS: Japanese National Health Insurance System Table 3 Table 3 shows the differences in cost for dVS surgery for 100, 200 or 300 robotic cases per year at 1 institution with the projected JNHIS reimbursement system. RATS: robot-assisted thoracic surgery; dVS: da Vinci ® Surgical System; VATS: video-assisted thoracic surgery; JNHIS: Japanese National Health Insurance System operations are now increasing rapidly in Japan. The total number of dVS operations in Japan was 209 in 2009, 498 in 2010, and 971 in 2011. Rapid decisions concerning JNHIS applications for dVS operations are necessary for many other procedures.
Good long-term outcomes from robotic surgery for thymectomy with nonthymomatous myasthenia gravis and lobectomy for non-small cell lung cancer have recently been reported. [4] [5] [6] These reports also show satisfactory outcomes for RATS. In the near future, these reports will encourage many thoracic surgeons to attempt to widen the indications of robotic surgery in Japan.
As for the clinical hypothesis in Japan, it appears that no final conclusion can be reached unless the number of cases of RATS increases. Past reports 4, 5) are retrospective investigations in the field of thoracic surgery. However, such clinical evidence is not yet shown even in other fields, particularly in urology, and evidence showing a significant difference is only available for thymectomy by RATS for myasthenia gravis. We consider that RATS, if fairly priced, would be worth performing for thoracic disease in Japan. It appears that randomize prospective studies in RATS are necessary in the future. Such studies are essential because the medical cost is high, which is the first practical issue that needs to be addressed to solve this clinical problem. As a result, accumulation of sufficient number of cases evaluated by randomized prospective studies is expected to bring about medico-economic improvement. These series of studies enable cost-benefit analysis leading to the reduction of the medical cost which can finally pave the way for the extension of the benefits of robotic surgery to many patients.
The clinical use of a dVS in Japan began in 2006, and even today only a few hospitals and institutions possess it. As of April 2012, 45 dVS systems were being used for clinical or educational purposes in Japan. Because only a few hospitals can afford it, even for government-sanctioned procedures such as prostatectomy, only those relatively few hospitals will accumulate many more patients, at the expense of other hospitals and perhaps to the detriment of some patients. The JNHIS has covered the whole nation of Japan since 1961. Now the medical copayment the patients have to pay is 30%, with all their other medical expenses being paid by the government. Regardless of the lower per capita medical costs for Japan in comparison with other countries, because all prices are fixed by the government, the tendency of medical costs to increase annually continues to be a point of much political disagreement. The background is complicated and includes Japan's rapidly aging society, advanced medical developments and the increasing cost of drugs. To limit the national health care financial burden as much as possible, the Japanese Government must always consider improving and controlling the medical insurance system which means that the costs of robotic surgery are problematic.
The Japanese medical reimbursement assignment revision by the Ministry of Health, Labour and Welfare in April 2012 did not accept the dVS robotic system as a basic medical instrument. Instead, dVS robot-assisted surgery was approved, under several detailed conditions, for example, the experience of the users, as additional technical support in the insurance system, that is, it was considered medical technology supporting a surgical procedure.
However, despite the enormous potential for the spread and development of robotic surgery in various fields, including the field of telemedicine, the single greatest negative feature preventing this, at least in Asia, is the hugely greater cost of the equipment in Japan, Korea and Taiwan.
The cost of a dVS system in Japan is US$3255000 (November 2012 exchange rate), despite the fact that Japan only applies a 7% sales tax, but no import tax. The cost in Korea is similar. Thus, as of September 2011 the cost in Japan was 2.17 times that in the US (US$1500000), 1.46 times that in the UK and 1.59 times that in Germany and France. Despite repeated requests for an explanation for this from the manufacturer, no satisfactory answer has been forthcoming.
One possible related factor is that Intuitive Surgical Inc. is the sole manufacturer of the dVS device and there are as yet no other comparable competitive systems on the market. 7) Despite our ignorance of the intricacies of patent law that are related to the present situation, we are sanguine that, as competition for such devices spreads, the attendant lower prices might stimulate increases in the applications of and education in RAS.
In establishing its policy regarding remuneration for RAS techniques, the Japanese government decided, for whatever reason, that RAS is not a basic medical technique, but rather an "add-on" technological support system. In defense of this policy, it can only be said that with a population of 127570000, of whom 30740000 are over 65 and 16650000 are under 16, the Japanese government is constantly caught in a conundrum whereby they must seek to provide best possible care but yet not pay exorbitant amounts.
The fact remains that, under the present system, any given institution in Japan would have to be able to perform 300 or more procedures annually to break even financially, and few institutions are willing to take on that responsibility.
There are several limitations to this study. The first two concern financial matters: i.e., the pricing policy of the dVS manufacturer is absolutely opaque, while the second is that the remuneration policy of the Japanese government is equally murky. Thirdly, unless it is made possible for clinicians to explore possible wider indications of the equipment, as well as the true value of RAS and RATS for patients, institutions and health systems, it may take a long time for these procedures to be understood and implemented.
We believe that it is essential for these primarily financial concerns to be clearly addressed in order for the benefits of RAS to reach the public.
Conclusion
Because of the high cost of the system in Japan, it is necessary to perform dVS surgery at least 300 times in a year at one institution to prevent a deficit in income. We hope that marked competition will eventually reduce the cost of robot-related devices. Without a large decrease in cost of the system, it is difficult to envision rapid spread and development of RAS even in countries with highly developed national insurance systems.
